CASI Pharmaceuticals (CASI) Shares Up 9.7%
CASI Pharmaceuticals, Inc. (NASDAQ:CASI)’s share price shot up 9.7% during trading on Friday . The stock traded as high as $3.18 and last traded at $3.06. 526,731 shares were traded during trading, an increase of 90% from the average session volume of 277,383 shares. The stock had previously closed at $2.79.
Several research firms recently commented on CASI. HC Wainwright reaffirmed a “buy” rating and set a $2.00 target price on shares of CASI Pharmaceuticals in a report on Friday, September 8th. Maxim Group reaffirmed a “buy” rating and set a $4.00 target price on shares of CASI Pharmaceuticals in a report on Friday, September 8th. Finally, ValuEngine raised shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 15th.
CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. equities analysts anticipate that CASI Pharmaceuticals, Inc. will post -0.15 earnings per share for the current year.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Stock Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related stocks with our FREE daily email newsletter.